Glioblastoma: The Emerging Challenges in Rapidly Evolving Social Changes

Dear Colleagues,

Glioblastoma remains a devastating diagnosis, with a poor prognosis (12–14 months) and standard therapy dating back to 2005. Since then, technical refinements have improved precision, enabling more personalized treatment based on tumor markers, radiomics, tractography, neuropshycology, and other advances.

At the same time, society has undergone rapid change. An increasing number of external variables—often unclear—have posed formidable challenges for early diagnosis and for tailoring optimal therapies to the individual and their specific context. Such extra-personal factors include immigration and cultural differences, metropolitan settlement, web-induced misinformation, and economic constraints affecting both social welfare and individual out-of-pocket resources. As a consequence, real-world clinical outcomes increasingly diverge from those observed in clinical trials.

This Special Issue seeks to bridge this gap by reviewing new therapies and assessing the impact of personal and societal factors in trials and related research. Topics of interest include methods for studying social determinants of cancer; patient-reported outcome measures; individual health- and non-health-related factors in high-grade glioma; strategies to address disparities within health systems; and best practices and policies to improve health and welfare.

Prof. Dr. Andrea Talacchi
Dr. Andrea Pace
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.